Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06467344 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 10 to 11
    • Eligibility criteria expanded, about 7 words
    • Publications: details revised at 1 of 1 entry
  2. Enrollment target: 13 to 15v10
  3. Eligibility criteria revisedv9
  4. Site details revised at 1 of 10 sitesv8
  5. Study title expanded, about 1 wordv7
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 2 of 10 sitesv6
  2. Site details revised at 1 of 10 sitesv5
  3. Study sites: 4 to 10v4
  4. Re-verified, no change to tracked fieldsv3
  5. Start date changed from estimate of Jun 29, 2024 to Jun 11, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Trial Details
NCT Number NCT06467344
Lead Sponsor Ascidian Therapeutics, Inc
Conditions
(from sponsor)		 Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Related terms Cone-Rod Dystrophies, Stargardt Disease
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov